Literature DB >> 4017954

The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form.

S R George, M Watanabe, T Di Paolo, P Falardeau, F Labrie, P Seeman.   

Abstract

In order to determine whether the high affinity state or the low affinity state of the dopamine receptor mediated the inhibition of release of PRL by dopamine agonists, a large number of dopaminergic agonists (n = 31) and antagonists (n = 24) were tested for their potencies to inhibit the binding of [3H] spiperone to porcine anterior pituitary tissue, and for their potencies to affect the release of PRL from rat anterior pituitary cells in culture. All agonists (except bromocriptine, ergocryptine, and dihydroergocryptine) inhibited [3H]spiperone binding in two phases: one phase occurred at nanomolar or subnanomolar concentrations (representing the high affinity state of the dopamine receptor) and the other phase occurred at much higher concentrations of agonist (the low affinity state of the dopamine receptor). The dissociation constants (K) for each drug at each state were derived by computer, with the program LIGAND. It was observed that the agonist K values for the high affinity state were virtually identical with those agonist concentrations inhibiting PRL release; the K values for the low affinity state were about 2 orders higher. These data suggest that the high affinity state of the D2 dopamine receptor is the functional state which mediates the inhibition of PRL release.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4017954     DOI: 10.1210/endo-117-2-690

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

1.  [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.

Authors:  Jinbin Xu; Babak Hassanzadeh; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2010-06       Impact factor: 2.562

2.  [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.

Authors:  Jinbin Xu; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2009-09       Impact factor: 2.562

3.  Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis.

Authors:  Philip Seeman; David Weinshenker; Remi Quirion; Lalit K Srivastava; Sanjeev K Bhardwaj; David K Grandy; Richard T Premont; Tatyana D Sotnikova; Patricia Boksa; Mufida El-Ghundi; Brian F O'dowd; Susan R George; Melissa L Perreault; Pekka T Männistö; Siobhan Robinson; Richard D Palmiter; Teresa Tallerico
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

4.  DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum.

Authors:  Mikaeel Valli; Sang Soo Cho; Mario Masellis; Robert Chen; Pablo Rusjan; Jinhee Kim; Yuko Koshimori; Alexander Mihaescu; Antonio P Strafella
Journal:  Mol Neurobiol       Date:  2019-03-08       Impact factor: 5.590

Review 5.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

6.  (18)F-MCL-524, an (18)F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study.

Authors:  Sjoerd J Finnema; Vladimir Stepanov; Ryuji Nakao; Anna W Sromek; Tangzhi Zhang; John L Neumeyer; Susan R George; Philip Seeman; Michael G Stabin; Cathrine Jonsson; Lars Farde; Christer Halldin
Journal:  J Nucl Med       Date:  2014-05-01       Impact factor: 10.057

7.  Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand.

Authors:  Nicholas Seneca; Mette Skinbjerg; Sami S Zoghbi; Jeih-San Liow; Robert L Gladding; Jinsoo Hong; Pavitra Kannan; Edward Tuan; David R Sibley; Christer Halldin; Victor W Pike; Robert B Innis
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

8.  Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Authors:  Ariel Graff-Guerrero; Matthaeus Willeit; Nathalie Ginovart; David Mamo; Romina Mizrahi; Pablo Rusjan; Irina Vitcu; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

9.  Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Authors:  Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero
Journal:  Synapse       Date:  2016-07-11       Impact factor: 2.562

10.  Guanine nucleotide binding proteins mediate D2 dopamine receptor activation of a potassium channel in rat lactotrophs.

Authors:  L C Einhorn; G S Oxford
Journal:  J Physiol       Date:  1993-03       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.